FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

For research purposes only. Full disclaimer →

Stack Library

Executive Performance Protocol

Cognitive Enhancementintermediate
25
Share
Peptides

3

Avg Daily mcg

3,900

Level

intermediate

Added

May 16, 2026

Overview

The Executive Performance Protocol is an intermediate-level cognitive enhancement stack designed for professionals, entrepreneurs, and knowledge workers who demand sustained mental clarity, emotional resilience, and neuroprotective support. This three-peptide combination targets multiple cognitive pathways simultaneously—attention and working memory, stress adaptation, and long-term neuronal health. Semax at 900mcg daily is a synthetic analogue of ACTH(4-10) developed at the Institute of Molecular Genetics in Russia. It powerfully upregulates Brain-Derived Neurotrophic Factor (BDNF), the key neurotrophin responsible for neuroplasticity, learning, and long-term memory formation. Semax enhances dopaminergic and serotonergic neurotransmission, improving focus, motivation, and mental stamina without the jitteriness or crash of stimulants. Clinical research has demonstrated its efficacy in improving attention, cognitive processing speed, and recovery from mental fatigue. At 900mcg, this represents a robust nootropic dose. Selank at 500mcg daily is an anxiolytic peptide based on tuftsin that modulates GABA activity and reduces excessive stress signaling. It provides calm, clear-headed focus by reducing the cognitive interference caused by anxiety and rumination. Selank also enhances memory encoding and emotional regulation, making it particularly valuable during high-pressure decision-making. Its immunomodulatory properties provide an additional layer of support for executives under chronic stress. Epithalon at 5000mcg every other day provides long-term neuroprotection by maintaining telomere integrity in neuronal cells and supporting healthy pineal function. The pineal gland regulates not only sleep but also broader neuroendocrine rhythms essential for sustained cognitive performance. Epithalon ensures that the performance gains from Semax and Selank are built on a foundation of cellular longevity. Protocol Notes: Semax and Selank are administered intranasally for rapid CNS absorption, ideally in the morning or before demanding cognitive work. Epithalon is injected subcutaneously on alternating days. This stack is ideal for professionals managing heavy cognitive loads, students during intensive study periods, or anyone seeking reliable mental performance without stimulant dependency. Typical cycles are 30-60 days with periodic breaks.

Dosing Protocol

900 mcg

per dose

500 mcg

per dose

Epithalon

Every other day

Read more about Epithalon →

5,000 mcg

per dose

Goals & Evidence

Evidence tier:community

Comments

Sign in to join the discussion

Disclaimer: This stack is community-submitted and for research purposes only. Peptide Contacts does not verify the safety or efficacy of submitted stacks. Always consult a qualified healthcare professional before using any peptide protocol.